Last updated: 11/20/2020 20:00:04
Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD)
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Other
Other
Trial overview
Official title: Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD) - A Placebo-controlled, Single-Blind Comparative Study -
Trial description: This is a single-blind, placebo-controlled, parallel group study to evaluate the efficacy of BRL29060A (paroxetine hydrochloride hydrate, hereafter paroxetine) administered orally over the dose range of 20 mg to 50 mg once daily after supper for 12 weeks in Japanese patients with posttraumatic stress disorder (PTSD) as assessed by the change from baseline in CAPS-SX total score. Also the effect of paroxetine on regional cerebral blood flow (rCBF) induced by subthreshold emotional arousing (or symptom stimulating) tasks will be determined using functional magnetic resonance imaging (fMRI) for exploratory assessment of the correlation between the change in rCBF and the efficacy.The sample size is 30 subjects. The study period consists of 4 weeks of run-in phase, 12 weeks of treatment phase, 0-3 weeks of taper phase and follow-up examination at 2 weeks after the last dose, for a total of 18-21 weeks.Subjects will visit the clinic at the start of run-in phase, Week -2, the start of treatment phase, Weeks 2, 4, 6, 8 and 12 of treatment, and follow-up examination.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Single (Participant)
Allocation:
Randomized
Primary outcomes:
Number of participants with the indicated change from baseline in CAPS-SX (Clinician-Administered Post traumatic Stress Disorder (PTSD) Scale One Week Symptom Status Version) total score at Week 12
Timeframe: Baseline and Week 12
Secondary outcomes:
Number of participants with the indicated Week 0 and Week 12 z-scores for regional blood flow using functional magnetic resonance imaging (fMRI) in the left amygdala (LA), right amygdala (RA), and the medial prefrontal cortex (MPFC)
Timeframe: Baseline and Week 12
Number of participants with the indicated change from baseline in CAPS-SX (Clinician-Administered Post traumatic Stress Disorder [PTSD] Scale One Week Symptom Status Version) total score at Weeks 4 and 8
Timeframe: Baseline and Weeks 4 and 8
Number of participants with the indicated change from baseline in CAPS-SX (Clinician-Administered Post traumatic Stress Disorder [PTSD] Scale One Week Symptom Status Version) relating re-experiencing at Weeks 4, 8, and 12
Timeframe: Baseline and Weeks 4, 8, and 12
Number of participants with the indicated change from baseline in CAPS-SX (Clinician-Administered Post traumatic Stress Disorder [PTSD] Scale One Week Symptom Status Version) relating avoidance and numbing at Weeks 4, 8, and 12
Timeframe: Baseline and Weeks 4, 8, and 12
Number of participants with the indicated change from baseline in CAPS-SX (Clinician-Administered Post traumatic Stress Disorder [PTSD] Scale One Week Symptom Status Version) relating increased arousal symptom at Weeks 4, 8, and 12
Timeframe: Baseline and Weeks 4, 8, and 12
Number of participants with the indicated change from baseline in CGI (Clinical Global Impression) severity of illness scores at Weeks 2, 4, 6, 8, 10, and 12
Timeframe: Baseline and Weeks 2, 4, 6, 8, 10, and 12
Number of participants with a Clinical Global Impression (CGI) Global Improvement of 4 at Week 12
Timeframe: Week 12
Interventions:
Enrollment:
5
Primary completion date:
2008-11-12
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
This study has not been published in the scientific literature.
Medical condition
Post-Traumatic Stress Disorder
Product
paroxetine
Collaborators
Not applicable
Study date(s)
January 2008 to December 2008
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
20 - 65 years
Accepts healthy volunteers
No
- Patients who are primarily diagnosed with PTSD (Posttraumatic Stress Disorder: 309.81) using DSM-IV-TR criteria. The CAPS-DX (Clinician-Administered PTSD Scale-DX) and M.I.N.I. (The Mini International Neuropsychiatric Interview, Japanese version 5.0.0. [2003]) will be used for diagnosis
- Pathologic condition: Patients who experienced a motor vehicle accident (MVA) with severe or potential severe physical injury more than 3 months ago but less than 12 months ago
- Patients primarily diagnosed with a DSM-IV-TR Axis I disorder other than PTSD (e.g. major depressive disorder, dysthymic disorder, specific phobia [simple phobia], obsessive-compulsive disorder, panic disorder, etc.) within 6 months of week -4 (start of baseline phase)
- Patients presenting with a current major depressive episode that preceded the diagnosis of PTSD
Inclusion and exclusion criteria
Inclusion criteria:
- Patients who are primarily diagnosed with PTSD (Posttraumatic Stress Disorder: 309.81) using DSM-IV-TR criteria. The CAPS-DX (Clinician-Administered PTSD Scale-DX) and M.I.N.I. (The Mini International Neuropsychiatric Interview, Japanese version 5.0.0. [2003]) will be used for diagnosis
- Pathologic condition: Patients who experienced a motor vehicle accident (MVA) with severe or potential severe physical injury more than 3 months ago but less than 12 months ago
- Patients aged 20 and <65 at the time of signing the Informed consent
- Male and female patients
- Inpatient/outpatient status: Both are permitted
- Patients who are able to give written informed consent in person (i.e., patients who are capable of giving written informed consent on their own)
- Patients whose combined score of the CAPS-SX standard B, C, and D is over 50
Exclusion criteria:
- Patients primarily diagnosed with a DSM-IV-TR Axis I disorder other than PTSD (e.g. major depressive disorder, dysthymic disorder, specific phobia [simple phobia], obsessive-compulsive disorder, panic disorder, etc.) within 6 months of week -4 (start of baseline phase)
- Patients presenting with a current major depressive episode that preceded the diagnosis of PTSD
- Patients receiving disability payments due to PTSD or other psychiatric diseases
- Patients currently engaged in compensation litigation whereby personal gain would be achieved from prolonged symptoms of PTSD or any other psychiatric disorders
- Patients who meet the DSM-IV-TR criteria for substance abuse or dependence (alcohol or drugs) within 6 months of Week -4 (start of baseline phase)
- Patients with history of a suicide attempt within 6 months before Week -4 (start of baseline phase), or have, in the opinion of the investigator, "C. high risk of suicide" according to the MINI at Week -4
- Patients who are pregnant, lactating or of childbearing potential and are likely to become pregnant
- Patients receiving electro-convulsive therapy (ECT) prior to Week -4 (start of baseline phase)
- Patients receiving another investigational product within 12 weeks before Week -4 (start of baseline phase)
- Patients with a history or complication of manic psychosis
- Patients with a history or complication of convulsive disorder (epilepsy, etc.)
- Patients with a diagnosis or complication of a cognitive disorder (MMSE <=24 points)
- Patients with a history and complication of serious cerebral organic disorder. (e.g. cerebrovascular disorder, meningitis, degenerative disease and other neurological disorders and seizures; however, bleeding in the upper arachnoid membrane should not be excluded)
- Patients unable or unwilling to undergo the fMRI procedure (e.g., cerebrovascular clipping surgery, pacemaker, any internal metals with magnetism, and claustrophobia)
- Patients with glaucoma
- Patients with a known tendency for bleeding or those with predisposing conditions
- Patients with a history of hypersensitivity to paroxetine
- Patients with serious physical symptoms (cardiac, hepatic and renal dysfunction, or hematopoietic dysfunction, etc.). For seriousness, Grade 3 of "Criteria for seriousness of adverse reactions to drugs, etc. (Yakuan No.80)" is used as an index
- Patients with a history or complication of cancer or malignant tumour
- Patients with chronic hepatitis type B and/or C which is positive of hepatitis B surface antigen (HBsAg) and/or hepatitis C antibody
- Others whom the investigator or sub-investigator considers ineligible for or unable to participate in the investigation
- Criteria at Week 0 (start of Treatment Phase): Subjects whose drug compliance rate for Drug 1 (Run-in Phase placebo) is <80% between Week -4 and Week 0; Subjects whose CAPS-SX total score of the standard B, C, and D at Week 0 varied by 25% or more compared with those at Week -2
Trial location(s)
Showing 1 - 6 of 11 Results
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Other
Actual primary completion date
2008-11-12
Actual study completion date
2008-11-12
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website